CombiGene
Business Services · Sweden · 1-10 Employees
View Company Info for Free
Overview
Headquarters
Agavägen 52a, Lidingoe, Stockholm, Swede...Phone Number
+46 852800399Website
www.combigene.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About CombiGene
CombiGene's vision is to offer patients affected by severe life-changing diseases opportunities for a better life through innovative gene therapies. CombiGene's business concept is to develop effective gene therapies for serious diseases that today lack adequate treatment methods. Research assets are taken in from a network of external researchers and developed further up to clinical concept verification. Drug candidates for common diseases will be co-developed and commercialized through strategic partnerships, while CombiGene may drive the development and commercialization in-house for medicines aimed at limited patient populations. The Company has signed an exclusive collaboration and licensing agreement for CombiGene's CG01 project with Spark Therapeutics. The company is public and listed on the Nasdaq First North Growth Market and the company's Certified Advisor is FNCA Sweden AB, +46 (0)852 80 03 99, info@fnca.se.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is CombiGene your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when CombiGene launches new products
Click to see if CombiGene had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on CombiGene recently announced quarterly report
Check if CombiGene has recently received funding, and reach out quickly before it becomes old news!
Check out if CombiGene is spiking on competitors!
CombiGene, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at CombiGene
Funding: Get notified immidiatlly once CombiGene has new funding data
Website visits: Recent activity has been detected on your website
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Company Profile Activity
Activity Insights
CombiGene is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
CombiGene is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about CombiGene.
CombiGene Tech Stack
A closer look at the technologies used by CombiGene
See more technologies
Most Recent Scoops
Promotion
Executive Move
Left Company
Executive Move
Promotion
Executive Move
Left Company
Executive Move
Executive Move
Board of Directors
CombiGene News & Media
BioStock: CombiGene focuses on the pain project
In CombiGene’s Q3 report, the terminated agreement with Spark Therapeutics takes up considerable space, for obvious reasons. However, the report highlights that the gene therapy company is now focusing on the COZY1 pain project. They have chosen both a production partner and a collaborator for upcoming preclinical toxicology studies, along with indications for the clinical trial program. Read the article at biostock.se: https://www.biostock.se/en/2023/11/combigene-focuses-on-the-pain-project/ ThBioStock: CombiGene’s CEO on the terminated collaboration with Spark
Over the weekend, CombiGene received the news that Spark Therapeutics has terminated the collaboration agreement for the epilepsy project CG01. BioStock reached out to CEO Peter Ekolind for a comment on the unexpected announcement and what prompted the decision. Read the interview with Peter Ekolind at biostock.se: https://www.biostock.se/en/2023/10/combigenes-ceo-on-the-terminated-collaboration-with-spark/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biosBioStock: CombiGene’s new CEO talks about his visions for the company
Jan Nilsson, CEO of gene therapy company CombiGene since 2016, has left his post and last Friday Peter Ekolind, former COO, took over as the new CEO. Ekolind, previously CEO of Getinge Sweden, tells BioStock that CombiGene is in a dynamic and exciting phase with the potential to achieve several milestones in the future. Read the full interview with Peter Ekolind at biostock.se: https://www.biostock.se/en/2023/09/combigenes-new-ceo-talks-about-his-visions-for-the-company/ This is a press releaseBioStock: CombiGene’s CEO gives a status update
Jan Nilsson, CEO at CombiGene, visited BioStock’s studio to talk about the company’s second quarter. The discussion also covers the collaboration with Zyneyro and the development of new treatments targeting severe chronic pain conditions. We also learn more about a recent meeting with partner Spark Therapeutics, and Nilsson’s stepping down as CEO. Additionally, the interview introduces the new CEO, Peter Ekolind, and explores Nilsson’s future role at CombiGene. Watch the studio interview with Ja
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Frequently Asked Questions Regarding CombiGene
Sign Up For FreeTo access detailed company insights
CombiGene's vision is to offer patients affected by severe life-changing diseases opportunities for a better life through innovative gene therapies. CombiGene's business concept is to develop effective gene therapies for serious diseases that today lack adequate treatment methods. Research assets are taken in from a network of external researchers... Read More
